Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Engineered Interleukin-2 (IL-2) selective for antigen activated T cells”In the company’s words, NCT05098132 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
- Main trialPhase 1/2
- “This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.”In the company’s words, NCT05098132 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Jan 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jan 2029 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026